Literature DB >> 33738064

Biological Evaluation of 5'-(N-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors.

Dilip K Tosh1, Christopher M Brackett2, Young-Hwan Jung1, Zhan-Guo Gao1, Monimoy Banerjee2, Brian S J Blagg2, Kenneth A Jacobson1.   

Abstract

The heat shock protein 90 kDa (Hsp90) family of chaperones is highly sought-after for the treatment of cancer and neurodegenerative diseases. Glucose regulated protein 94 (Grp94) is the endoplasmic reticulum localized isoform that is responsible for the maturation of proteins involved in cell adhesion and the immune response, including Toll-like receptors, immunoglobulins, and integrins. Consequently, Grp94 has been implicated in many different diseases including cancer metastasis, glaucoma, and viral infection. 5'-(N-Ethylcarboxamido)adenosine (NECA) was identified from a high-throughput screen as one of the first molecules to exhibit isoform selectivity toward Grp94, with the ethyl group projecting into a unique pocket within the ATP binding site of Grp94. This pocket has since been exploited by several groups to develop Grp94 selective inhibitors. Despite success in the development of other classes of inhibitors, relatively little work has been done to further develop inhibitors with the NECA scaffold. Unfortunately, NECA is also a potent adenosine receptor agonist, which is likely to confound any biological activity. Therefore, structure-activity relationship studies were performed on the NECA scaffold leading to the discovery of several molecules that displayed similar selectivity and affinity as the parent compound.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 33738064      PMCID: PMC7957913          DOI: 10.1021/acsmedchemlett.0c00509

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  32 in total

1.  Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability.

Authors:  F Randow; B Seed
Journal:  Nat Cell Biol       Date:  2001-10       Impact factor: 28.824

2.  Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.

Authors:  Pallav D Patel; Pengrong Yan; Paul M Seidler; Hardik J Patel; Weilin Sun; Chenghua Yang; Nanette S Que; Tony Taldone; Paola Finotti; Ralph A Stephani; Daniel T Gewirth; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2013-09-01       Impact factor: 15.040

3.  Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma.

Authors:  Andrew R Stothert; Amirthaa Suntharalingam; Dustin J E Huard; Sarah N Fontaine; Vincent M Crowley; Sanket Mishra; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

4.  Purification and characterization of the adenosine A2-like binding site from human placental membrane.

Authors:  K A Hutchison; I H Fox
Journal:  J Biol Chem       Date:  1989-11-25       Impact factor: 5.157

5.  Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism.

Authors:  Amirthaa Suntharalingam; Jose F Abisambra; John C O'Leary; John Koren; Bo Zhang; Myung Kuk Joe; Laura J Blair; Shannon E Hill; Umesh K Jinwal; Matthew Cockman; Adam S Duerfeldt; Stanislav Tomarev; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

6.  Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation.

Authors:  Karen L Soldano; Arif Jivan; Christopher V Nicchitta; Daniel T Gewirth
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

7.  2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors.

Authors:  Zhan-Guo Gao; Liaman K Mamedova; Peiran Chen; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2004-11-15       Impact factor: 5.858

8.  Development of a fluorescence polarization assay for the molecular chaperone Hsp90.

Authors:  Joungnam Kim; Sara Felts; Laura Llauger; Huazhong He; Henri Huezo; Neal Rosen; Gabriela Chiosis
Journal:  J Biomol Screen       Date:  2004-08

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Overexpression of molecule GRP94 favors tumor progression in lung adenocarcinoma by interaction with regulatory T cells.

Authors:  Xiao-Feng Duan; Ya-Wei Xin
Journal:  Thorac Cancer       Date:  2020-01-22       Impact factor: 3.500

View more
  2 in total

Review 1.  Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.

Authors:  Kenneth A Jacobson; Veronica Salmaso; R Rama Suresh; Dilip K Tosh
Journal:  RSC Med Chem       Date:  2021-07-13

Review 2.  Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?

Authors:  Jana Kotulová; Marián Hajdúch; Petr Džubák
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.